BriaCell Therapeutics Corp. (CVE:BCT – Get Free Report)’s stock price fell 3.8% during trading on Thursday . The stock traded as low as C$10.60 and last traded at C$10.60. 3,402 shares changed hands during mid-day trading, a decline of 73% from the average session volume of 12,671 shares. The stock had previously closed at C$11.02.
Wall Street Analyst Weigh In
Separately, HC Wainwright cut their price target on BriaCell Therapeutics from C$18.00 to C$15.00 in a report on Thursday, September 19th.
View Our Latest Research Report on BriaCell Therapeutics
BriaCell Therapeutics Stock Down 3.8 %
About BriaCell Therapeutics
BriaCell Therapeutics Corp., an immuno-oncology biotechnology company, engages in developing approaches for the management of cancer. Its lead candidate is Bria-IMT that is in Phase I/IIa clinical trial in a combination study with immune checkpoint inhibitors for the treatment of breast cancer. The company also has a cooperative research and development agreement with the National Cancer Institute for developing Bria-OTS, an off-the-shelf personalized immunotherapy for advanced breast cancer; and BriaDx, a diagnostic test.
Recommended Stories
- Five stocks we like better than BriaCell Therapeutics
- 3 Healthcare Dividend Stocks to Buy
- MercadoLibre Targets Double-Digit Upside with Argentina Boom
- How to Effectively Use the MarketBeat Ratings Screener
- Domino’s Pizza Stock Delivers: A Hot Buy for Growth Investors
- What is a Death Cross in Stocks?
- 3 Small-Cap Stocks Ready to Deliver Significant Growth
Receive News & Ratings for BriaCell Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BriaCell Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.